Measuring pseudobulbar affect in ALS

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue SUPPL. 1, 2004, Pages 99-102

  Smith, Richard A ^a   Berg, James E ^b   Pope, Laura E ^b   Thisted, Ronald A ^c  

^a The Center for Neurologic Study   (United States)

^b AVANIR PHARMACEUTICALS   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DOPAMINE; ENZYME INHIBITOR; LEVODOPA; LEVORPHANOL; QUINIDINE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BRAIN STEM; CEREBELLUM; DIAGNOSTIC IMAGING; DISEASE CLASSIFICATION; DRUG METABOLISM; DRUG POTENTIATION; EMOTIONALITY; HUMAN; MENTAL INSTABILITY; PRIORITY JOURNAL; PSEUDOBULBAR PALSY; RATING SCALE; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; VALIDATION PROCESS;

AMYOTROPHIC LATERAL SCLEROSIS; ELECTROMYOGRAPHY; ENDPOINT DETERMINATION; HUMANS; MUSCLE WEAKNESS; NEUROPSYCHOLOGICAL TESTS; PSEUDOBULBAR PALSY; REGRESSION ANALYSIS; TIME FACTORS;

EID: 6444235764     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/17434470410020058     Document Type: Article

References (10)

1. Darwin C. The expression of the emotions in man and animals. New York and London: D Appleton and Company, 1872.
2. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am J Psychiatry 1993; 150: 286-293.
3. Mukand J, Kaplan M, Senno RG, Bishop DS. Pathological crying and laughing: treatment with sertraline. Arch Phys Med Rehabil 1196; 77: 1309-1311.
4. Nahas Z, Arlinghaus KA, Kotria KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotinin reuptake inhibitors. J Neuropsychiatry Clin Neurosci 1998; 10: 453-455.
5. Newsome-Davis IC, Abrahams LH, Goldstein LH, Leigh N. The emotional lability questionnaire: a new measure of emotional lability in amyotrophic lateral sclerosis. J Neurological Sciences 1999; 169: 22-25.
6. Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA. A self-report measure of affective lability. J Neurol, Neurosurg and Psych 1997; 63: 89-93.
7. Smith RA, Moore SR, Gresham LS, Manley PE, Licht JM. The treatment of affective lability in ALS patients with dextromethorphan. Neurology 1995; 45: A330.
8. Parvivzi P, Anderson SW, Martin CO, Damasio H, Damasio AR. Pathological laughter and crying/link to the cerebellum. Brain 2001; 124: 1708-1719.
9. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmac and Therap 1992; 51: 647-655.
10. Musacchio JM, Klein M, Paturzo JJ. Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine. Mol Pharmacol 1989; 35(1): 1-5.